How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,084 results for

Sublingual Immunotherapy

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Subcutaneous and Sublingual Immunotherapy in Allergic Asthma in Children (PubMed)

Subcutaneous and Sublingual Immunotherapy in Allergic Asthma in Children This review presents up-to-date understanding of immunotherapy in the treatment of children with allergic asthma. The principal types of allergen immunotherapy (AIT) are subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT). Both of them are indicated for patients with allergic rhinitis and/or asthma, who have evidence of clinically relevant allergen-specific IgE, and significant symptoms despite reasonable

Full Text available with Trip Pro

2017 Frontiers in pediatrics

102. Tinnitus after administration of sublingual immunotherapy (PubMed)

Tinnitus after administration of sublingual immunotherapy Sublingual immunotherapy was first described in 1986. Since then, its use has been increased as an alternative to subcutaneously administered immunotherapy in the treatment of allergic rhinitis. The most common side effects are of oropharyngeal and gastrointestinal in nature, for example, itching, swelling, irritation, ulceration of the oropharynx and nausea, abdominal pain, diarrhoea, and vomiting. More severe side effects are dominated (...) by systemic and respiratory tract manifestations.In this clinical case, the author reports a right-sided transient tinnitus lasting for 48 h after administration of sublingual immunotherapy for house dust mite in allergic rhinitis.This case provide important insights for clinical practice, as tinnitus has not been previously reported as a side effect of sublingual immunotherapy with house dust mite allergens.

Full Text available with Trip Pro

2017 SAGE Open Medical Case Reports

103. Sublingual house dust mite immunotherapy has no impact on decrease of circulating erythrocytes upon airway allergen challenge in allergic rhinitis (PubMed)

Sublingual house dust mite immunotherapy has no impact on decrease of circulating erythrocytes upon airway allergen challenge in allergic rhinitis House dust mite (HDM) allergy is a predominant cause for perennial allergic rhinitis (AR) in Europe. We recently reported that circulating erythrocyte numbers decrease after airway allergen challenge in a murine asthma model and in grass-pollen sensitized AR subjects. Consequently, we aimed to evaluate these findings in HDM sensitized AR subjects (...) and the influence of preceding allergen immunotherapy. Seventy-seven (age 26.8 ± 7.3 years; 54.5% female) HDM-allergic rhinitis subjects previously enrolled in a randomized, monocentric sublingual immunotherapy (SLIT) trial at the Vienna Challenge Chamber (VCC) were included. Subjects had either received placebo (n = 22), low-dose HDM (n = 29) or high-dose HDM specific sublingual immunotherapy (n = 26) daily for 24 weeks. Blood sampling was performed before and after 6 hours of HDM allergen exposure. Overall

Full Text available with Trip Pro

2017 Scientific reports

104. Erratum: In Vitro Evaluation of Allergen Potencies of Commercial House Dust Mite Sublingual Immunotherapy Reagents (PubMed)

Erratum: In Vitro Evaluation of Allergen Potencies of Commercial House Dust Mite Sublingual Immunotherapy Reagents This corrects the article on p. 124 in vol. 7, PMID: 25729619.

Full Text available with Trip Pro

2017 Allergy, asthma & immunology research

105. Sublingual versus subcutaneous immunotherapy: patient adherence at a large German allergy center (PubMed)

Sublingual versus subcutaneous immunotherapy: patient adherence at a large German allergy center Many placebo-controlled studies have demonstrated that allergen immunotherapy (AIT) is an effective therapy for treating allergies. Both commonly used routes, subcutaneous (SCIT) and sublingual immunotherapy (SLIT), require high patient adherence to be successful. In the literature, numbers describing adherence vary widely; this investigation compares these two routes of therapy directly.All data

Full Text available with Trip Pro

2017 Patient preference and adherence

106. Corrigendum: Subcutaneous and Sublingual Immunotherapy in Allergic Asthma in Children (PubMed)

Corrigendum: Subcutaneous and Sublingual Immunotherapy in Allergic Asthma in Children [This corrects the article on p. 82 in vol. 5, PMID: 28484690.].

Full Text available with Trip Pro

2017 Frontiers in pediatrics

107. Quality of life improvement after a three-year course of sublingual immunotherapy in patients with house dust mite and grass pollen induced allergic rhinitis: results from real-life (PubMed)

Quality of life improvement after a three-year course of sublingual immunotherapy in patients with house dust mite and grass pollen induced allergic rhinitis: results from real-life Along with its high prevalence, the burden of allergic rhinitis rests upon the serious impact on quality of life of patients. Allergic rhinitis is associated with impairments in daily activities, work and school performance, and practical problems. Patients suffer from sleep disorders and emotional problems. Тhe (...) advantages of sublingual immunotherapy on quality of life have only recently begun to emerge. The objective of this prospective real-life study was to evaluate the effect of a three-year course of sublingual immunotherapy with house dust mite (HDM) and grass pollen extracts on quality of life in adults with allergic rhinitis.A total number of 191 adult patients [105 (54,979%) men; mean age 27.3 years (SD-6.14)] with moderate to severe allergic rhinitis and clinically relevant sensitization to house dust

Full Text available with Trip Pro

2017 Health and quality of life outcomes

108. Debut of Gastroesophageal Reflux Concomitant with Administration of Sublingual Immunotherapy (PubMed)

Debut of Gastroesophageal Reflux Concomitant with Administration of Sublingual Immunotherapy Gastroesophageal reflux disease (GORD) is an often debilitating condition characterised by retrograde flow of content from stomach into the oesophagus, where the low pH of the stomach acid irritates the mucosa of the oesophagus. The most dominant symptoms in GORD are pyrosis, regurgitation, and dysphagia. Sublingual immunotherapy (SLIT) was first described in 1986. Following this description, the use (...) to administration of sublingual immunotherapy for house dust mite in allergic rhinitis. The patient had to stop the SLIT after two weeks of administration due to GORD. The cessation resulted in rapid resolution of symptoms.

Full Text available with Trip Pro

2017 Case reports in gastrointestinal medicine

109. Enhanced efficacy of sublingual immunotherapy by liposome-mediated delivery of allergen (PubMed)

Enhanced efficacy of sublingual immunotherapy by liposome-mediated delivery of allergen Immunotherapy by sublingual administration of allergens provides high patient compliance and has emerged as an alternative to subcutaneous immunotherapy for the treatment of IgE-associated allergic diseases. However, sublingual immunotherapy (SLIT) can cause adverse events. Development of allergen delivery systems enabling more efficient delivery and hence lower allergen load might reduce the adverse events (...) . In the present study, we have investigated neutral and cationic liposomes as delivery systems of ovalbumin (OVA), as a model allergen, in an OVA-induced allergic airway inflammation model. We investigated the liposome carriers' ability to improve tolerance induction of antigens compared to the corresponding dose of free OVA. Mice were treated sublingually over 2 weeks with free or liposome encapsulated OVA followed by intraperitoneal injections and intranasal challenge. Mice sublingually treated with OVA

Full Text available with Trip Pro

2017 International journal of nanomedicine

110. Sublingual immunotherapy in children with allergic polysensitization. (PubMed)

Sublingual immunotherapy in children with allergic polysensitization. Polysensitization is quite frequent in allergic children and may cause difficulties for the allergist in prescribing allergen-specific immunotherapy. This study aimed at evaluating the clinical effectiveness of 1 year of sublingual immunotherapy (SLIT) in a cohort of Italian allergic children with polysensitization. This open study was performed on 51 polysensitized children (34 boys; mean age, 11.8 years; range, 5.2-17.7

2017 Allergy and Asthma Proceedings

111. A systematic review and economic evaluation of subcutaneous and sublingual allergen immunotherapy in adults and children with seasonal allergic rhinitis.

A systematic review and economic evaluation of subcutaneous and sublingual allergen immunotherapy in adults and children with seasonal allergic rhinitis. Severe allergic rhinitis uncontrolled by conventional medication can substantially affect quality of life. Immunotherapy involves administering increasing doses of a specific allergen, with the aim of reducing sensitivity and symptomatic reactions. Recent meta-analyses have concluded that both subcutaneous immunotherapy (SCIT) and sublingual (...) immunotherapy (SLIT) are more effective than placebo in reducing symptoms. It is uncertain which route of administration is more effective and whether or not treatment is cost-effective.To determine the comparative clinical effectiveness and cost-effectiveness of SCIT and SLIT for seasonal allergic rhinitis in adults and children.Electronic databases {MEDLINE, EMBASE, The Cochrane Library [Cochrane Central Register of Controlled Trials (CENTRAL)], NHS Economic Evaluation Database (NHS EED)} and trial

Full Text available with Trip Pro

2017 Health technology assessment (Winchester, England)

112. Efficacy and safety of 4 months of sublingual immunotherapy with recombinant Mal d 1 and Bet v 1 in patients with birch pollen-related apple allergy. (PubMed)

Efficacy and safety of 4 months of sublingual immunotherapy with recombinant Mal d 1 and Bet v 1 in patients with birch pollen-related apple allergy. Birch pollen-related apple allergy is among the most prevalent food allergies in adolescent/adult subjects and mainly results from sensitization to the major birch pollen allergen Bet v 1 and subsequent cross-reaction with the apple protein Mal d 1. However, specific immunotherapy with birch pollen has inconsistent effects on apple allergy.We (...) sought to compare the safety and efficacy of sublingual immunotherapy (SLIT) with 2 formulations containing either rMal d 1 or rBet v 1 on birch pollen-related apple allergy.Sixty participants with birch pollen-related apple allergy were randomized to daily sublingual application of placebo (n = 20) or 25 μg of rMal d 1 (n = 20) or rBet v 1 (n = 20) for 16 weeks. Adverse events were regularly recorded. Sublingual challenges with standardized doses of rMal d 1, skin prick tests with recombinant

2017 Journal of Allergy and Clinical Immunology

113. Sublingual immunotherapy-induced IL-10 production is associated with changed response to the decongestion test: preliminary results. (PubMed)

Sublingual immunotherapy-induced IL-10 production is associated with changed response to the decongestion test: preliminary results. Sublingual immunotherapy (SLIT) has been shown to be capable of inducing a regulatory T-cell response as evidenced by IL-10 production. Decongestion testing consists of spraying an intranasal vasoconstrictor drug to evaluate the recovery of nasal airflow limitation. The aim of this study was to assess the association of SLIT-induced IL-10 production with nasal

2017 Allergy and Asthma Proceedings

114. Sublingual immunotherapy for allergic rhinitis

Sublingual immunotherapy for allergic rhinitis Sublingual immunotherapy for allergic rhinitis Sublingual immunotherapy for allergic rhinitis Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Sublingual immunotherapy for allergic rhinitis. Lansdale: HAYES, Inc.. Directory Publication. 2011 Authors' conclusions Sublingual immunotherapy involves the administration (...) of a diluted dose of an allergen under the tongue, which allows the material to contact the oral mucosa. Sublingual immunotherapy has been investigated in patients with allergic rhinitis and/or asthma associated with sensitivity to seasonal allergens, and to allergens such as dust mites, mold, pet dander, or nuts. In contrast to standard immunotherapy, which requires subcutaneous injections, sublingual therapy may offer a lower risk of serious side effects, and may be more comfortable and acceptable

2011 Health Technology Assessment (HTA) Database.

115. Sublingual immunotherapy for allergic rhinitis: subjective versus objective tools to evaluate its success. (PubMed)

Sublingual immunotherapy for allergic rhinitis: subjective versus objective tools to evaluate its success. Biomarkers that enable objective evaluation of the clinical effects of immunotherapy for allergic rhinitis have yet to be identified.This study included 40 patients who were enrolled in a large randomized, double-blind, placebo-controlled, multicenter study examining the efficacy of sublingual immunotherapy (SLIT) using Japanese cedar (JC) pollen extract during two consecutive pollen

2016 Rhinology

116. SQ grass sublingual allergy immunotherapy tablet for disease-modifying treatment of grass pollen allergic rhinoconjunctivitis. (PubMed)

SQ grass sublingual allergy immunotherapy tablet for disease-modifying treatment of grass pollen allergic rhinoconjunctivitis. Allergy immunotherapy is a treatment option for allergic rhinoconjunctivitis (ARC). It is unique compared with pharmacotherapy in that it modifies the immunologic pathways that elicit an allergic response. The SQ Timothy grass sublingual immunotherapy (SLIT) tablet is approved in North America and throughout Europe for the treatment of adults and children (≥5 years old

2016 Allergy and Asthma Proceedings

117. Importance of Quality of Life for Adherence to Sublingual Immunotherapy (PubMed)

Importance of Quality of Life for Adherence to Sublingual Immunotherapy Background. Nonperception of efficacy ranks among the most commonly cited causes for nonadherence to sublingual immunotherapy (SLIT). Quality of life (QoL) in patients is a determining factor influencing adherence. We investigated QoL and adherence separately in SLIT patients at one pediatric practice in Germany. Methods. We conducted a noninterventional, cross-sectional, retrospective, quality-of-life survey among

Full Text available with Trip Pro

2016 BioMed research international

118. Long-term effects of a house dust mite sublingual immunotherapy tablet in an environmental exposure chamber trial. (PubMed)

Long-term effects of a house dust mite sublingual immunotherapy tablet in an environmental exposure chamber trial. Treatment with SQ house dust mite (HDM) sublingual immunotherapy (SLIT) tablet is effective for HDM respiratory allergic disease, but data on long-term effects are lacking.Post hoc analyses were conducted to determine the long-term effect of SQ HDM SLIT-tablet on nasal, ocular, and cough symptoms 1 year after discontinuation of treatment.Study participants underwent environmental

2016 Asthma & Immunology

119. The Efficacy of Sublingual Immunotherapy for Allergic Rhinitis May Vary with the Time of Day. (PubMed)

The Efficacy of Sublingual Immunotherapy for Allergic Rhinitis May Vary with the Time of Day. Sublingual immunotherapy (SLIT) is a safe and effective treatment for allergic rhinitis (AR). However, many issues regarding SLIT remain to be resolved, including the optimal timing of administration. This study investigated the effect of time of day on SLIT efficacy with the goal of optimizing the therapeutic outcome.We performed prophylactic SLIT at different times of day (10 a.m. or 10 p.m.) in 2 (...) mouse models of AR: an ovalbumin (OVA)-induced AR model and Cry j 1-induced AR model, and compared the effects.In the OVA-induced AR model, mice sublingually receiving OVA at 10 a.m. exhibited a greater decrease in total and OVA-specific IgE levels than mice treated at 10 p.m. In addition, mice treated at 10 a.m. exhibited reductions in OVA-specific IL-4, IL-10, and IL-13 production by splenocytes relative to mice treated at 10 p.m. Furthermore, we observed a more efficient capture of sublingually

Full Text available with Trip Pro

2016 International Archives of Allergy and Immunology

120. Methodological aspects of a meta-analysis of grass pollen allergen sublingual immunotherapy tablets. (PubMed)

Methodological aspects of a meta-analysis of grass pollen allergen sublingual immunotherapy tablets. 27084407 2018 07 06 2018 12 02 1097-6825 138 1 2016 07 The Journal of allergy and clinical immunology J. Allergy Clin. Immunol. Methodological aspects of a meta-analysis of grass pollen allergen sublingual immunotherapy tablets. 314-315.e4 10.1016/j.jaci.2016.01.039 S0091-6749(16)00365-1 Cox Linda S LS College of Osteopathic Medicine, Nova Southeastern University, Davie, Fla. Electronic address (...) immunology Pollen immunology Sublingual Immunotherapy Tablets 2015 08 27 2016 01 20 2016 01 29 2016 4 17 6 0 2016 4 17 6 0 2018 7 7 6 0 ppublish 27084407 S0091-6749(16)00365-1 10.1016/j.jaci.2016.01.039

2016 The Journal of allergy and clinical immunology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>